Blar i SINTEF Industri på forfatter "Ochando, Jordi"
-
Cyclic Arginine–Glycine–Aspartate-Decorated Lipid Nanoparticle Targeting toward Inflammatory Lesions Involves Hitchhiking with Phagocytes
Sofias, Alexandros Marios; Bjørkøy, Geir; Ochando, Jordi; Sønstevold, Linda; Hegvik, Maria; Davies, Catharina de Lange; Haraldseth, Olav; Lammers, Twan; Mulder, Willem J. M.; Hak, Sjoerd (Peer reviewed; Journal article, 2021)Active-targeting nanomedicine formulations have an intricate in vivo behavior. Nanomedicines developed to target endothelial αvβ3-integrin are recently demonstrated to display extensive uptake by circulating phagocytes. ... -
Tumor Targeting by αvβ3-Integrin-Specific Lipid Nanoparticles Occurs via Phagocyte Hitchhiking
Sofias, Alexandros Marios; Toner, Yohana C.; Meerwaldt, Anu E.; van Leent, Mandy M. T.; Soultanidis, Georgios; Elschot, Mattijs; Gonai, Haruki; Grendstad, Kristin; Flobak, Åsmund; Neckmann, Ulrike; Wolowczyk, Camilla; Fisher, Elizabeth L.; Reiner, Thomas; Davies, Catharina de Lange; Bjørkøy, Geir; Teunissen, Abraham J. P.; Ochando, Jordi; Pérez-Medina, Carlos; Mulder, Willem J. M.; Hak, Sjoerd (Peer reviewed; Journal article, 2020)Although the first nanomedicine was clinically approved more than two decades ago, nanoparticles’ (NP) in vivo behavior is complex and the immune system’s role in their application remains elusive. At present, only ...